Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

[摘要] BackgroundGoserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.Case presentationHere we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.ConclusionGoserelin plus endocrine treatments may benefit male breast cancer.

[发布日期] 2014-12-23

[关键词] Male breast cancer;Goserelin;Endocrine treatment;Family time